摘要
恩替卡韦(entecavir,ETV)可快速强效抑制乙型肝炎病毒复制并且具有高耐药基因屏障被美国、欧洲和亚太等各大国际肝病学会和我国肝病学会指南推荐为治疗慢性乙型肝炎(chronic hepatitis B,CHB)的一线药物本文对ETV治疗CHB的研究进展,包括ETV的治疗依从性、ETV对各种类型CHB患者的疗效、对ETV部分应答、治疗失败或耐药的管理、ETV的停药时机、ETV和聚乙二醇干扰素联合/序贯方案以及对ETV治疗患者肝细胞癌的监测进行综述.
Entecavir（ETV） is a potent hepatitis B virus inhibitor with a high barrier to resistance,and it has been recommended as one of the first-line drugs for treating chronic hepatitis B（CHB） by guidelines from several international and national societies.This paper reviews the recent advances in the treatment of CHB with ETV,in terms of treatment adherence,efficacy in the treatment of various kinds of patients with CHB,management of patients with partial virological response,viral resistance or treatment failure to ETV,treatment cessation,sequential or combination therapy with ETV and pegylated interferon,as well as the surveillance of hepatocellular carcinoma.
出处
《世界华人消化杂志》
CAS
2017年第1期7-16,共10页
World Chinese Journal of Digestology
